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Abstract
Attention has recently focused on new cancer immunotherapy protocols aiming to activate T cell mediated anti-tumor
responses. To this end, administration of antibodies that target inhibitory molecules regulating T-cell cytotoxicity has
achieved impressive clinical responses, as has adoptive cell transfer (ACT) using expanded tumor infiltrating lymphocytes
(TIL) or genetically modified cytotoxic T cells. However, despite clear clinical responses, only a fraction of patients respond
to treatment and there is an urgent call for characterization of predictive biomarkers. CD8 positive T cells can infiltrate
tumor tissues and destroy HLA class I positive tumor cells expressing the specific antigen. In fact, current progress in the
field of cancer immune therapy is based on the capacity of T cells to kill cancer cells that present tumor antigen in the
context on an HLA class I molecule. However, it is also well established that cancer cells are often characterized by loss or
down regulation of HLA class I molecules, documented in a variety of human tumors. Consequently, immune therapy
building on CD8 T cells will be futile in patients harboring HLA class-I negative or deficient cancer cells. It is therefore
mandatory to explore if these important molecules for T cell cytotoxicity are expressed by cancer target cells. We have
indications that different types of immunotherapy can modify the tumor microenvironment and up-regulate reduced
HLA class I expression in cancer cells but only if the associated molecular mechanisms is reversible (soft). However, in case
of structural (hard) aberrations causing HLA class I loss, tumor cells will not be able to recover HLA class I expression and
as a consequence will escape T-cell lysis and continue to growth. Characterization of the molecular mechanism
underlying the lack or downregulation of HLA class I expression, seems to be a crucial step predicting clinical
responses to T cell mediated immunotherapy, and possibly aid the selection of strategies that could condition
patients for response. Thus, characterization of HLA expression by cancer cells could therefore represent an
important predictive marker for immunotherapy of cancer.
Keywords: HLA expression, Predictive markers, HLA loss, Immune evasion, Checkpoint inhibition, Adoptive cell
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Background
The field of immunotherapy has experienced tremendous
breakthroughs over the past few years. To this end, the
FDA approval of Sipuleucell T for the treatment of hor-
mone refractory prostate cancer set the stage in 2010 [1],
followed by the more recent approvals of the PD-1 and
CTLA-4 checkpoint inhibitory monoclonal antibodies
(mAb) in melanoma and non-small cell lung cancer
(NSCLC) [2]. Importantly, numerous immunoregulatory
mAb aimed at blocking inhibitory or boosting stimulatory
immune signaling are in development, some of which have
already been in clinical testing alone or in combination
with the already approved blocking antibodies with prom-
ising data, e.g., CD40 agonistic antibody in melanoma [3].
Also, the use of adoptive cell transfer (ACT) using in vitro
expanded tumor infiltrating lymphocytes (TIL) have shown
very strong clinical efficacy in phase II trials [4, 5], and the
administration of T cells harnessed with tumor specific
T-cell receptors, show great promise also beyond solid
cancer, e.g., myeloma [6]. To the latter point, also sol-
uble monoclonal TCR fusion proteins targeting the
HLA/peptide complex and the CD3 molecule are in clin-
ical testing. Despite these tremendous breakthroughs in
the field it is clear that only a fraction of patients respond
to treatment underscoring the need to characterize pre-
dictive biomarkers that would allow selection of patients
for individual therapies.
The search for predictive biomarkers is ongoing and
current approaches are scrutinizing immune infiltration,
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expression of the target molecules in the tumor micro-
environment, unique genetic hits (e.g., KRAS mutations),
phenotypes of T cells among PBMC or TIL, or global
mutational load of the cancer cells, just to mention a
few. Several of these characteristics of the cancer cells,
the microenvironment, or the immune system have
shown correlation with response providing interesting
new insight into the biology, and in some cases the
mechanisms of action in response to therapy. Nonethe-
less, further work is certainly necessary to elucidate bio-
markers that will allow prediction and selection of
patients that are prone to respond to treatment. To this
end, studies of the actual target of cytotoxic T cells
(HLA class I molecules) seem to be strangely missing.
At the same time, it has been widely accepted that the
majority of tumors lose HLA class I expression. Thus,
there is consensus that CD8 T cells are the main effector
cells engaged with killing of cancer cells but in most
studies it is left unrevealed whether the cancer cells
express the actual target: the HLA class I molecules [7].
Main text
It is well established that the immune system recognize
cancer cells, and data are accumulating that spontaneous
T-cell responses impact on overall survival [8, 9]. The
co-existence of an anti-tumor response with a progres-
sing tumor, highlight that cancer cells eventually escape
the immunological response and several mechanisms of
immune escape have been suggested [10]. Obviously,
characterization of mechanisms of escape could lead to
development of immunological strategies that interact
with prominent escape routes. To this end, one could
argue that the clinical success of targeting the PD-1/PDL-
1 axis builds on blocking an interaction that contributes
to escape from tumor specific T cells at the tumor site.
However, the prerequisite for a successful T-cell response
is HLA class I expression on the surface of cancer cells,
since clearly the absence or down regulation of HLA class
I leave the T cell incapable of recognizing the cancer cell.
HLA class I loss or downregulation has been described
in human tumors of different origin with percentages
that range from 60 to 90 % [11–14]. Two types of tumor
HLA class I alterations are known: 1) caused by revers-
ible or ‘soft’ regulatory defects leading to the coordinated
downregulation of genes encoding, HLA class I complex,
and components of the antigen processing and presenta-
tion machinery; and 2) structural or ‘hard’ irreversible
alterations caused by mutational events and chromo-
somal abnormalities, affecting the HLA class I heavy
chain and β2m genes [15]. The reversible ‘soft’ tumor
HLA class I deficiencies show low mRNA levels of spe-
cific genes (heavy chain, β2m, and APM) that seem to
be coordinately down regulated and they can be cor-
rected in vitro by IFN-γ or other cytokines.
Among the ‘hard’ lesions, the loss of heterozygosity
(LOH) of chromosome 6p21 is an important mechanism
that generates HLA haplotype loss in various human
tumors with high incidence. Mutations in β2m gene and
loss of another gene copy due to LOH in chromosome
15 are responsable for the irreversible total loss of HLA
class I expression, and it has been described in various
types of malignancies, both in cell lines and in tumor tis-
sues [16]. It is evident that alteration in the expression
of any of the HLA class I molecules can affect both T
and NK cell-mediated immunity, with an impact on the
tumorigenic phenotype, metastatic capacity, and resist-
ance to immunotherapy in various types of cancer.
The analysis of HLA class I antigens in tumor tissues
requires a complex approach since HLA class I heavy
chain is highly polimorfic and needs the analysis of the
expression of six HLA class I alleles on tumor cells sur-
face which differ among cancer patients [17]. Frozen tis-
sue obtained from cancer patients in coordination with
pathologists is commonly analyzed by immunohistology.
Microdissection of tumor tissue is currently used to ob-
tain DNA and RNA from particular stroma or tumor
areas to define the molecular defects responsible for
HLA class I alterations. A more precise definition of the
tumor phenotype and of the underlying mechanism of
HLA class I defects can be obtained by the combined
use of these techniques together with polymerase chain
reaction (PCR), comparative genomic hybridization and
loss of heterozygosity (LOH) analysis with specific markers
spanning the chromosomal region of interest.
High degree of tumor infiltration with T cells is con-
sidered to be a good prognostic factor and has been
included into a new tumor immunological grading sys-
tem called “immunoscore” [18]. Different groups includ-
ing ours have observed in various types of cancers, that
the HLA class I negative tumors lack TILs. In contrast,
HLA class I positive tumors are characterized by high
degree of intratumoral infiltration with CD8+ T cells
[19]. In this context, it have been reported that the pro-
gression or regression of melanoma metástasis after im-
munotherapy was associated with HLA class I down or
upregulation and T cell low or high infiltration respect-
ively in two mixed responders patients [20], indicating
that both parameters are closely related. We favor the
idea that the status of intratumoral infiltration, reflects
the stage of cancer immune escape during natural can-
cer progression. At early stages there are more HLA
class I -positive tumor cells and many TILs, while at
more advanced stages the tumor contains more HLA
class I negative escape variants and T cells are outside
the tumor tissue restrained in the peritumoral area, in
the stroma. T cell immune selection of HLA class I
negative variants is a major mechanism to generate
tumor escape variants present in many human tumors
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[21]. The additive effect of studying HLA class I expres-
sion in tumors rely in the posibility to define the
molecular mechanism responsible for the HLA class I
loss or dowregulation. If it is reversible/soft, different
immunotherapy approaches will have the capacity to up-
regulate HLA class I associated antigen presentation and
induce tumor rejection [15, 21]. In contrast, if it is irre-
versible/hard, antigen presentation via HLA I molecules
will be bloked and resistant to any type of conventional
immunoterapy. The question that come immediately is
“what to do when a irreversible/hard mechanism is diag-
nosed” ? We have suggested and succesful tested “in
vitro” and “in vivo” the posibility to transfer wild type
HLA class I or beta2 microglobuline genes to restore the
HLA class I expression and T cell recognition [22, 23]
but other posibilities are open and have been recently
discussed [21].
There are recent trials published in which different
immune status markers were analyzed including the
HLA expression. Tjin et al. [24] studied 27 melanoma
tissues before tumor cell vaccination using autologous
GM-CSF transduced tumor cells and compared with 16
patients who were not vaccinated. More infiltrating CD4
and CD8 positive cells were found in non progressors
compared with progressors and T cell infiltration corre-
lated with overall survival. These authors also reported
that the loss of HLA A2 expression in melanoma
inversely correlated with the functional activation of
melanoma reactive T cell responses indicating that the
presence of HLA class I on tumors cells determine the T
cell effector function [25]. These results are in agreement
with those obtained by Ryschich et al. [8] in pancreatic
carcinoma in which T cell infiltration correlated with the
HLA class I expression i.e., more T cells in tissues that
were HLA class I positive and vice versa suggesting an ac-
tive ongoing process of T cell immuneselection of HLA
class I negative tumor variants. In phase II and III clinical
trials using ipilimumab, melanoma patients were typed in
for HLA-A2 and HLA-A1 in peripheral blood lympho-
cytes. Median overall survival was similar in both groups
regardless of their HLA class I status [26]. The idea that
HLA class I expression can be a predictive marker for the
final oucome of a particular immunotherapy trial rely on
the tumor tissue analysis for HLA class I expression. We
know that the frequency of HLA class I losses in diferent
tumor tissues is very high when a carefull analysis is
performed including HLA class I ABC total loss, HLA
haplotype loss, HLA allelic loss or HLA class I ABC
downregulation. These findings suggest that the HLA
class I associated tumor escape mechanism is underesti-
mated when performing basic tumor tissue analysis and
therefore patients suppossed to be positive in the tumor
tissue for a particular HLA class I allele, are not. In this
context, the absence of expression in the tumor tissue of
three HLA- class I A,B,C alleles (a chromosome six loss)
or event a single HLA- class I allele loss can be suffi-
cient to prevent the presentation of the strong tumor
rejection antigen to T cells and generate a tumor escape
variant [27].
Cancer immunotherapy is finally beginning to deliver on
its promise. However, even with the most successful drugs
or their combinations, most patients either do not respond
or eventually succumb to disease despite initial response.
Thus, characterization of biomarkers is essential.
To this end, the tumor microenvironment is clearly of
huge importance in the sense that tumors with a (T cell)
inflamed environment are more prone to respond to ad-
ministration of checkpoint inhibitory mAb [28]. Along
these lines, response to PD-1 therapy has been shown to
correlate with expression of PDL1 in the tumor micro-
environment [29]. The immunogenicity of the cancer
cells is similarly important. Thus, mutations may lead to
immune responses against neo-antigens, which may be
broadly applicable e.g., KRAS mutations in pancreatic
cancer [30], or may be patient specific unique mutations
matching only a single HLA allele [31]. To this end, it is
clear that at least a fraction of the antigens recognized
by TIL are mutated peptides [32], and through techno-
logical advances the possibility to routinely target such
peptides is no longer wishful thinking or belong in a
distant future [32].
Thus, it is clear that both in terms of strength of the
immune responses, i.e. what can be induced by unleash
of in situ T cells by blocking of inhibitory molecules, as
well as in terms of specificity by targeting of mutated
peptides, the tools at hand are much improved.
As mentioned, however, there is an urgent call for pre-
dictive markers for response, and there seem to be a mis-
conception in the field. Thus, considering PD-1 therapy as
“targeting therapy”, it obviously makes at least some sense
to study expression of PDL-1 also underscored by the cor-
relation with response. However, it should be kept in mind
that PDL-1 is really not the target that directly leads to
killing of cancer cells. Similarly, concerning neo-antigens,
the mutated protein and the peptide derived thereof is a
pre-requisite but is in fact not the target. The target is the
mutated peptide in context of the appropriate HLA mol-
ecule. Goes without saying – the same can be said about
any immunotherapy that relies on a T-cell effector arm,
e.g., therapeutic vaccination.
Hence, over the past few years we have discovered
tools to target cancer cells with much more powerful
approaches while at the same time with a much higher
degree of specificity. However, quite often the target is
out of sight, in the sense that although HLA molecules
are the target, predictive markers are searched high and
low while HLA molecules seem somewhat out of the
spotlight.
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Conclusion
We propose that expression of HLA class I – global as
well as at the level of individual alleles, depending on
the immunological targeting strategy - is studied care-
fully as a potential predictive biomarker in immuno-
therapy. Prospectively, hard lesions e.g., genetic loss of
both alleles of the β2m in chromosome 15 or an HLA
haplotype loss affecting one chromosome six should
represent exclusion criteria [33]. In retrospective ana-
lyses, HLA expression data can be used to correlate
with response to therapy. As given above concerning
soft lesions, a low level expression of HLA class mole-
cules may be rectified by interferon-γ (IFN-γ) or
others TH1 type cytokines. Potentially, data from
retrospective analyses can form the basis of “condi-
tioning” prior to treatment thereby altering the micro-
environment. To this end, targeting of antigens
expressed not solely by cancer cells but by also cancer
stromal cells, e.g., IDO-1 [34] could lead to influx of
immune cells which in turn secrete IFN-γ, enabling
subsequent targeting also of the true target i.e. the
HLA molecules expressed by cancer cells. Even less
invasive strategies may be relevant. In conclusion, ana-
lyzing the expression of the true target - the HLA
molecule - will surely exclude patients that have very
limited chance for response, and also identify a group
of patients for which conditioning that leads to upreg-
ulation of HLA molecules will increase the chance of
response to therapy [7].
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